Showing results (121-130 of 232) with videos related to
Sort By:
Pageof 24
Gut|November 2, 2016
Effect of vedolizumab (anti-α4β7-integrin) therapy on histological healing and mucosal gene expression in patients with UCIngrid Arijs, Gert De Hertogh, Bart Lemmens, et al.European Journal of Pediatrics|August 2, 2008
Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel diseaseMirjam Bueno de Mesquita, Marc Ferrante, Liesbet Henckaerts, et al.Inflammatory Bowel Diseases|March 30, 2021
Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel DiseasesClaire Liefferinckx, Jérémie Bottieau, Jean-François Toubeau, et al.Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|May 11, 2010
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximabWilliam J Sandborn, Maria T Abreu, Geert D'Haens, et al.Inflammatory Bowel Diseases|December 6, 2018
Difference in Pathomechanism Between Crohn's Disease and Ulcerative Colitis Revealed by Colon TranscriptomeLili Yang, Shijie Tang, Susan S Baker, et al.Crohn'S & Colitis 360|March 31, 2023
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysisRemo Panaccione, Eric B Collins, Gil Y Melmed, et al.Journal of Crohn'S & Colitis|November 26, 2013
ABO histo-blood group might modulate predisposition to Crohn's disease and affect disease behaviorDiego Forni, Isabelle Cleynen, Marc Ferrante, et al.Journal of Crohn'S & Colitis|December 22, 2010
Serological markers are associated with disease course in ulcerative colitis. A study in an unselected population-based cohort followed for 10 yearsOle Høie, Geir Aamodt, Severine Vermeire, et al.Inflammatory Bowel Diseases|September 2, 2016
Interpreting Registrational Clinical Trials of Biological Therapies in Adults with Inflammatory Bowel DiseasesSubrata Ghosh, William J Sandborn, Jean-Frederic Colombel, et al.The American Journal of Gastroenterology|October 3, 2002
Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's diseaseSeverine Vermeire, Edouard Louis, An Carbonez, et al.Pageof 24